Trial Profile
LY2216684 Compared to Placebo as Adjunctive Therapy to SSRI in the Prevention of Symptom Re-emergence in Major Depressive Disorder
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Oct 2021
Price :
$35
*
At a glance
- Drugs Edivoxetine (Primary)
- Indications Major depressive disorder
- Focus Registrational; Therapeutic Use
- Sponsors Eli Lilly and Company
- 06 Feb 2014 New source identified and integrated (Korean Clinical Trials Register)
- 01 Nov 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 06 Feb 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.